Development and optimization of direct cell reprogramming
Direct reprogramming has significant implications for regenerative medicine, disease modeling, and potential therapeutic applications.
We are working on establishing reliable cell models for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Frontotemporal dementia (FTD), and glioblastoma which is crucial for testing bioactive compounds and potential therapeutic interventions.
Using these models researchers employ high-throughput screening techniques and various assays, including cell viability assays, apoptosis assays, and functional assays specific to the disease phenotype.
These models play a crucial role in early-stage drug discovery, allowing researchers to identify compounds with potential therapeutic effects on disease-related cellular processes.
Metabolism of neurooncology
We are focused on the investigation of neurooncology, tumors affecting the central nervous system (CNS), which includes the brain and spinal cord. One of the main research interests is the metabolism of glioblastoma cells and cells involved in neurofibromatosis pathology.
Second, searching for compounds modulating, targeting metabolism, and testing of bioactive compounds for drug discovery. We also have a stake in new techniques for early diagnostics of diseases.
Our holistic approach, combining a deep understanding of cellular metabolism, targeted drug development, rigorous testing of bioactive compounds, and innovative diagnostic techniques, is essential for advancing the field of neurooncology and improving patient outcomes. Interdisciplinary collaboration and leveraging cutting-edge technologies will be pivotal in making progress in these areas.
Development of exosome reprogramming technology of malignant cells
We are planning to cover various stages involved in exosome reprogramming technology for malignant cells, including the isolation and characterization of exosomes, as well as the development of new techniques for reprogramming or treating malignant brain tissues.
The development of exosome-based therapies for malignant brain tissues is an exciting and rapidly evolving field, with ongoing research aimed at refining techniques and advancing these approaches toward clinical applications. Collaborative efforts between researchers, clinicians, and industry partners will be critical for the successful translation of exosome reprogramming technology into effective cancer treatments.
Analysis of exosomes in reprogrammed cells
Analyzing exosomes in reprogrammed cells is crucial for understanding the effects of reprogramming and the potential therapeutic applications. Analyzing exosomes in reprogrammed cells is a multidimensional process that involves combining multiple techniques to gain a comprehensive understanding of their cargo and functional effects. This integrated approach is essential for advancing our knowledge and harnessing the therapeutic potential of exosomes in the context of cellular reprogramming.
Comparative analysis of exosomes in reprogrammed neurons obtained from healthy donors and patients with neurodegenerative diseases aims to provide a deep understanding of the differences in exosomal content between reprogrammed neurons from healthy donors and those from patients with neurodegenerative diseases. Such analyses contribute valuable insights into disease mechanisms, potential biomarkers, and therapeutic targets for neurodegenerative disorders.
New molecules for effective reprogramming, AI for metabolome analysis, rational drug design
The development of new molecules for effective cellular reprogramming is an active area of research, particularly in the context of regenerative medicine and disease modeling. Reprogramming typically involves converting one cell type into another, such as generating induced pluripotent stem cells (iPSCs) or directly converting one differentiated cell type into another. One of the key instruments we employ is bioinformatics and chemoinformatics.
Understanding the pathogenesis of complex neurodegenerative diseases or malignant diseases of neural tissue is impossible without an understanding of metabolism and its relationship to the genome. Bioinformatics and the application of modern ANNs allows us to discover hidden dependencies and features in the metabolome of cancer cells.
Finally, the third objective of AdVitam's Bioinformatics department is the intelligent development of novel small molecules for rare nervous system diseases and neurodegenerative diseases. We utilize the full state-of-the-art suite of methods for CADD - QSAR, molecular modeling & dynamics, HTVS, ANNs and others.
The field of reprogramming is dynamic, and ongoing research continues to unveil new molecules and strategies for improving efficiency, safety, and precision in cellular reprogramming. Collaborative efforts among researchers, clinicians, and industry partners are essential for translating these discoveries into practical applications for regenerative medicine and disease therapy.
